Literature DB >> 34075644

Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.

Marc Fishman1,2, Kevin Wenzel1, Jennifer Scodes3, Martina Pavlicova4, Aimee N C Campbell5, John Rotrosen6, Edward Nunes5.   

Abstract

BACKGROUND AND OBJECTIVES: Opioid use disorder (OUD) treatment outcomes are poorer for young adults than older adults. Developmental differences are broadly implicated, but particular vulnerability factor interactions are poorly understood. This study sought to identify moderators of OUD relapse between age groups.
METHODS: This secondary analysis compared young adults (18-25) to older adults (26+) from a comparative effectiveness trial ("XBOT") that randomized (N = 570) participants to extended-release naltrexone or sublingual buprenorphine-naloxone. We explored the relationship between 25 prespecified patient baseline characteristics and relapse to regular opioid use by age group and treatment condition, using logistic regression.
RESULTS: Young adults (n = 111) had higher rates of 24-week relapse than older adults (n = 459) (70.3% vs 58.8%) and differed on a number of specific characteristics, including more smokers, more intravenous opioid use, and more cannabis use. No significant moderators predicted relapse, in either three-way or two-way interactions. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: No baseline factors were identified as moderating the relationship between age group and opioid relapse, nor any interactions between baseline characteristics, age group, and treatment condition to predict opioid relapse. Poorer treatment outcomes for young adults are likely associated with multiple developmental vulnerabilities rather than any single predominant factor. Although not reaching significance, several characteristics (using heroin, smoking tobacco, high levels of depression/anxiety, or treatment because of family/friends) showed higher odds ratio point estimates for relapse in young adults than older adults. This is the first study to explore moderators of worse OUD treatment outcomes in young adults, highlighting the need to identify predictor variables that could inform treatment enhancements. (Am J Addict 2021;00:1-12).
© 2021 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34075644      PMCID: PMC8429062          DOI: 10.1111/ajad.13176

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  36 in total

Review 1.  Prevention and Treatment of Opioid Misuse and Addiction: A Review.

Authors:  Nora D Volkow; Emily B Jones; Emily B Einstein; Eric M Wargo
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

2.  Relapse prevention medications in community treatment for young adults with opioid addiction.

Authors:  Hoa T Vo; Erika Robbins; Meghan Westwood; Debra Lezama; Marc Fishman
Journal:  Subst Abus       Date:  2016-01-28       Impact factor: 3.716

3.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

4.  Cognitive deficits predict low treatment retention in cocaine dependent patients.

Authors:  Efrat Aharonovich; Deborah S Hasin; Adam C Brooks; Xinhua Liu; Adam Bisaga; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-09-19       Impact factor: 4.492

5.  Working Memory Training for Adolescents With Cannabis Use Disorders: A Randomized Controlled Trial.

Authors:  Mary M Sweeney; Olga Rass; Cara DiClemente; Rebecca L Schacht; Hoa T Vo; Marc J Fishman; Jeannie-Marie S Leoutsakos; Miriam Z Mintzer; Matthew W Johnson
Journal:  J Child Adolesc Subst Abuse       Date:  2018-04-10

6.  Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.

Authors:  Edward V Nunes; Jennifer M Scodes; Martina Pavlicova; Joshua D Lee; Patricia Novo; Aimee N C Campbell; John Rotrosen
Journal:  Am J Psychiatry       Date:  2021-06-25       Impact factor: 18.112

Review 7.  Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda.

Authors:  Frank J Vocci
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

8.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

9.  Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis.

Authors:  Laura B Monico; Ariel Ludwig; Elizabeth Lertch; Ross Dionne; Marc Fishman; Robert P Schwartz; Shannon Gwin Mitchell
Journal:  Addiction       Date:  2020-08-31       Impact factor: 6.526

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586

View more
  1 in total

Review 1.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.